Go Deep
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,356 | -22.2 | 2.41 | 0.04 | 4,121.43 |
| Oct 2026 | 19,297 | -22.3 | 2.42 | 0.04 | 4,098.65 |
| Oct 2026 | 19,406 | -21.9 | 2.37 | 0.04 | 4,000.77 |
| Oct 2026 | 19,612 | -20.9 | 2.27 | 0.04 | 3,814.99 |
| Oct 2026 | 19,680 | -21.5 | 2.23 | 0.04 | 3,757.61 |
| Oct 2026 | 19,871 | -19.7 | 2.14 | 0.04 | 3,587.80 |
| Oct 2026 | 19,651 | -20.8 | 2.25 | 0.04 | 3,777.48 |
| Oct 2026 | 19,494 | -21.5 | 2.33 | 0.04 | 3,909.28 |
| Oct 2026 | 19,497 | -21.5 | 2.33 | 0.04 | 3,897.73 |
| Oct 2026 | 19,400 | -21.9 | 2.38 | 0.04 | 3,971.02 |
| Oct 2026 | 19,554 | -21.2 | 2.30 | 0.04 | 3,857.63 |
Supernus Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 219,058,000.0 | 207,705,000.0 | 211,572,000.0 | 192,103,000.0 |
| Net Profit | -58,371,000.0 | -2,293,000.0 | -4,105,000.0 | -45,117,000.0 |
| EPS | -1.0 | -0.0 | -0.1 | -0.8 |
Supernus Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 718,952,000.0 | 661,817,000.0 | 607,521,000.0 | 667,238,000.0 | — |
| Net Profit | -38,550,000.0 | 73,865,000.0 | 1,316,000.0 | 60,711,000.0 | — |
| EPS | -0.7 | 1.3 | 0.0 | 1.1 | — |
Supernus Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,452,648,000.0 | 1,368,073,000.0 | 1,277,673,000.0 | 1,702,508,000.0 | — |
| Total Liabilities | 390,934,000.0 | 332,340,000.0 | 356,157,000.0 | 816,304,000.0 | — |
| Total Equity | 1,061,714,000.0 | 1,035,733,000.0 | 921,516,000.0 | 886,204,000.0 | — |
Owes vs Owns
Supernus Pharmaceuticals, Inc. owed $0.28 for every $1 it owned in Jun 2026, down from $0.48 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.28× | 0.27× | 0.24× | 0.28× | 0.48× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Supernus Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 21.2%Receivables 12.9%Inventory 5.7%Fixed assets (tangible) 0.7%Intangible assets 47.8%Other assets 11.6%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 2.1%Other liabilities 23.9%Shareholders' equity 73.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 308.7 | 453.6 | 254.9 | 461.3 |
| Receivables | 187.8 | 142.1 | 144.2 | 165.5 |
| Inventory | 82.4 | 54.3 | 77.4 | 91.5 |
| Fixed assets (tangible) | 10.5 | 11.5 | 13.5 | 15.2 |
| Intangible assets | 694.3 | 638.9 | 716.9 | 819.5 |
| Long-term investments | 0.0 | 0.0 | 16.6 | 93.9 |
| Other assets | 168.9 | 67.6 | 54.2 | 55.6 |
| Liabilities & equity | ||||
| Short-term debt | 10.6 | 6.9 | 8.3 | 402.0 |
| Long-term debt | 30.4 | 27.4 | 33.2 | 36.0 |
| Payables | 2.7 | 4.6 | 2.0 | 10.5 |
| Other liabilities | 347.3 | 293.5 | 312.7 | 367.8 |
| Shareholders' equity | 1,061.7 | 1,035.7 | 921.5 | 886.2 |
| Net tangible assets | 367.4 | 396.8 | 204.6 | 66.7 |
Supernus Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 47,331,000.0 | 171,951,000.0 | 111,085,000.0 | 116,826,000.0 | — |
| Investing Activities | 4,106,000.0 | -189,867,000.0 | 268,729,000.0 | -216,663,000.0 | — |
| Financing Activities | 9,130,000.0 | 12,193,000.0 | -397,880,000.0 | -10,477,000.0 | — |